Chembio Diagnostics, Inc. – NASDAQ:CEMI
Chembio Diagnostics stock price monthly change
Chembio Diagnostics stock price quarterly change
Chembio Diagnostics stock price yearly change
Chembio Diagnostics key metrics
Market Cap | 16.71M |
Enterprise value | 17.74M |
P/E | -0.62 |
EV/Sales | 0.22 |
EV/EBITDA | -0.53 |
Price/Sales | 0.13 |
Price/Book | 0.60 |
PEG ratio | -0.01 |
EPS | -0.81 |
Revenue | 48.33M |
EBITDA | -17.65M |
Income | -24.92M |
Revenue Q/Q | -48.27% |
Revenue Y/Y | 30.90% |
Profit margin | -50.36% |
Oper. margin | -48.91% |
Gross margin | 20.14% |
EBIT margin | -48.91% |
EBITDA margin | -36.52% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeChembio Diagnostics stock price history
Chembio Diagnostics stock forecast
Chembio Diagnostics financial statements
| Mar 2022 | 18.81M | -8.79M | -46.72% |
|---|---|---|---|
| Jun 2022 | 9.16M | -6.94M | -75.82% |
| Sep 2022 | 11.20M | -8.33M | -74.41% |
| Dec 2022 | 9.16M | -855.11K | -9.33% |
| Mar 2022 | 62890215 | 36.35M | 57.81% |
|---|---|---|---|
| Jun 2022 | 56055540 | 36.15M | 64.49% |
| Sep 2022 | 62179904 | 44.38M | 71.38% |
| Dec 2022 | 62611405 | 44.81M | 71.57% |
| Mar 2022 | -4.36M | -286.54K | -55.44K |
|---|---|---|---|
| Jun 2022 | -433.18K | -848.78K | -18.64K |
| Sep 2022 | -5.05M | -345.33K | 3.60M |
| Dec 2022 | -2.83M | 29.42K | -163.81K |
Chembio Diagnostics alternative data
| Aug 2023 | 188 |
|---|---|
| Sep 2023 | 188 |
| Oct 2023 | 188 |
| Nov 2023 | 188 |
| Dec 2023 | 188 |
| Jan 2024 | 188 |
| Feb 2024 | 188 |
| Mar 2024 | 188 |
| Apr 2024 | 188 |
| May 2024 | 188 |
| Jun 2024 | 188 |
| Jul 2024 | 188 |
Chembio Diagnostics other data
| Period | Buy | Sel |
|---|---|---|
| Apr 2023 | 1490120 | 0 |
| Quarter | Transcript |
|---|---|
| Q3 2022 6 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 7 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 8 May 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 3 Mar 2022 | Q4 2021 Earnings Call Transcript |
-
When is Chembio Diagnostics's next earnings date?
Unfortunately, Chembio Diagnostics's (CEMI) next earnings date is currently unknown.
-
Does Chembio Diagnostics pay dividends?
No, Chembio Diagnostics does not pay dividends.
-
How much money does Chembio Diagnostics make?
Chembio Diagnostics has a market capitalization of 16.71M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 30.91% to 48.34M US dollars.
-
What is Chembio Diagnostics's stock symbol?
Chembio Diagnostics, Inc. is traded on the NASDAQ under the ticker symbol "CEMI".
-
What is Chembio Diagnostics's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of Chembio Diagnostics?
Shares of Chembio Diagnostics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Chembio Diagnostics's key executives?
Chembio Diagnostics's management team includes the following people:
- Mr. Javan Esfandiari Executive Vice President and Chief Science & Technology Officer(age: 58, pay: $557,520)
- Mr. Richard L. Eberly Pres, Chief Executive Officer & Director(age: 64, pay: $556,030)
-
How many employees does Chembio Diagnostics have?
As Jul 2024, Chembio Diagnostics employs 188 workers.
-
When Chembio Diagnostics went public?
Chembio Diagnostics, Inc. is publicly traded company for more then 24 years since IPO on 18 Oct 2000.
-
What is Chembio Diagnostics's official website?
The official website for Chembio Diagnostics is chembio.com.
-
Where are Chembio Diagnostics's headquarters?
Chembio Diagnostics is headquartered at 555 Wireless Boulevard, Hauppauge, NY.
-
How can i contact Chembio Diagnostics?
Chembio Diagnostics's mailing address is 555 Wireless Boulevard, Hauppauge, NY and company can be reached via phone at +63 19241135.
Chembio Diagnostics company profile:
Chembio Diagnostics, Inc.
chembio.comNASDAQ
188
Medical - Diagnostics & Research
Healthcare
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
Hauppauge, NY 11788
CIK: 0001092662
ISIN: US1635722093
CUSIP: 163572209
